Viatris Inc. (VTRS) Return on Assets (ROA): -0.80%
Is Viatris Inc.’s return on assets (ROA) high or low?
Viatris Inc.'s return on assets (ROA) of -0.80% is 53% above its 5-year average of -1.68%, around the middle of its 5-year range (-9.45%–4.16%).
As of Sunday, June 21, 2026. 85.43% above its 12-month average of -5.49%.
VTRS Return on Assets (ROA) Chart
VTRS Average Return on Assets (ROA) Chart
VTRS Current vs Average Return on Assets (ROA) Chart
VTRS Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
-0.80%
RETURN ON ASSETS (ROA) AVG TTM
-5.49%
RETURN ON ASSETS (ROA) AVG 3Y
-1.68%
RETURN ON ASSETS (ROA) AVG 5Y
-1.68%
RETURN ON ASSETS (ROA) AVG 10Y
-0.57%
RETURN ON ASSETS (ROA) AVG 15Y
2.04%
RETURN ON ASSETS (ROA) AVG 20Y
2.26%
CURRENT VS TTM AVG
+85.43%
CURRENT VS 3Y AVG
+52.31%
CURRENT VS 5Y AVG
+52.52%
CURRENT VS 10Y AVG
-41.34%
CURRENT VS 15Y AVG
-139.29%
CURRENT VS 20Y AVG
-135.41%
VTRS Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viatris Inc. (VTRS) | $17.90B | -0.80% | -5.49% | -1.68% | -1.68% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.02B | 3.35% | 3.64% | 3.29% | 2.38% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 5.92% | 7.45% | 8.56% | 11.79% |
| Incyte Corporation (INCY)vs › | $19.62B | 19.51% | 9.54% | 8.43% | 7.44% |
| Labcorp Holdings Inc. (LH)vs › | $20.98B | 4.93% | 4.41% | 4.42% | 6.18% |
| DaVita Inc. (DVA)vs › | $13.34B | 4.47% | 4.84% | 4.27% | 4.56% |
| Medpace Holdings, Inc. (MEDP)vs › | $13.14B | 21.62% | 21.05% | 19.32% | 16.45% |
| Solventum Corporation (SOLV)vs › | $13.06B | 10.16% | 7.10% | 8.43% | 7.35% |
| Align Technology, Inc. (ALGN)vs › | $13.04B | 6.81% | 6.68% | 6.69% | 12.75% |
| United Therapeutics Corporation (UTHR)vs › | $22.78B | 19.17% | 16.59% | 14.73% | 13.22% |
Asset Efficiency
ROA
-0.8%
ROE
-2.0%
Viatris Inc. Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Viatris Inc. Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for Viatris Inc. (VTRS)?
- The return on assets (ROA) for VTRS stock is -0.80%.
- Is Viatris Inc.'s return on assets (ROA) high or low?
- Viatris Inc.'s return on assets (ROA) of -0.80% is 53% above its 5-year average of -1.68%, around the middle of its 5-year range (-9.45%–4.16%).
- What is the TTM average return on assets (ROA) for Viatris Inc. (VTRS)?
- The TTM average return on assets (ROA) for VTRS stock is -5.49%.
- What is the 3Y average return on assets (ROA) for Viatris Inc. (VTRS)?
- The 3Y average return on assets (ROA) for VTRS stock is -1.68%.
- What is the 5Y average return on assets (ROA) for Viatris Inc. (VTRS)?
- The 5Y average return on assets (ROA) for VTRS stock is -1.68%.
- What is the 10Y average return on assets (ROA) for Viatris Inc. (VTRS)?
- The 10Y average return on assets (ROA) for VTRS stock is -0.57%.
- What is the 15Y average return on assets (ROA) for Viatris Inc. (VTRS)?
- The 15Y average return on assets (ROA) for VTRS stock is 2.04%.
- What is the 20Y average return on assets (ROA) for Viatris Inc. (VTRS)?
- The 20Y average return on assets (ROA) for VTRS stock is 2.26%.
Viatris Inc. Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -9.45% |
| 2024-12-31 | -1.53% |
| 2023-12-31 | 0.11% |
| 2022-12-31 | 4.16% |
| 2021-12-31 | -2.31% |
| 2020-12-31 | -1.09% |
| 2019-12-31 | 0.05% |
| 2018-12-30 | 1.08% |
| 2017-12-30 | 1.94% |
| 2016-12-30 | 1.38% |
| 2015-12-30 | 3.81% |
| 2014-12-30 | 5.87% |
| 2013-12-30 | 4.08% |
| 2012-12-31 | 5.37% |
| 2011-12-31 | 4.63% |
| 2010-12-31 | 2.99% |
| 2009-12-31 | 2.15% |
| 2008-12-31 | -1.89% |
| 2007-12-31 | -13.37% |
| 2006-03-31 | 9.87% |
| 2005-03-31 | 9.53% |
| 2004-03-31 | 17.75% |
Related Metrics
About Viatris Inc.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Scott Andrew Smith